Ignite Creation Date:
2024-05-06 @ 8:21 AM
Last Modification Date:
2024-10-26 @ 11:58 AM
Study NCT ID:
NCT02713984
Status:
WITHDRAWN
Last Update Posted:
2020-03-19
First Post:
2016-03-12
Brief Title:
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Sponsor:
Zhi Yang
Organization:
Southwest Hospital China
Study Overview
Official Title:
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Status:
WITHDRAWN
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Reform CAR structure due to safety consideration
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chimeric antigen receptor T cells CAR-T therapy has not yet been fully explored in solid tumors Human epidermal growth factor receptor-2HER2 is widely expressed in cancers Investigators have developed anti-HER2 CAR-modified T cells and validated the efficiency targeting HER2-positive cancer in preclinical studies This study is aimed to confirm its adverse effects including cytokine storm response and any other adverse effects In addition CAR-T cells persistence tumor elimination and disease status after treatment will be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None